{"schema_version":"secwatch.filing_event.v1","accession":"0001439222-25-000087","form_type":"8-K","ticker":"AGIO","cik":"0001439222","company_name":"AGIOS PHARMACEUTICALS, INC.","filed_at":"2025-07-31T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.000448+00:00","generated_at":"2026-05-17T22:16:38.020688+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Agios Q2 2025 net loss $112M; PYRUKYND revenue $12.5M; PDUFA Sept 7 for thalassemia","bullets":["Net loss $112.0M vs $96.1M YoY; PYRUKYND net revenue $12.5M, up from $8.6M in Q2 2024.","Cash and marketable securities $1.3B; expects to fund potential thalassemia and SCD launches.","FDA PDUFA goal date for PYRUKYND sNDA in thalassemia is Sept 7, 2025; launch prep underway.","RISE UP Phase 3 topline for mitapivat in sickle cell disease on track by year-end 2025.","Dosed first patient in tebapivat Phase 2 for SCD; IND clearance for AG-236 siRNA for PV."],"urls":{"canonical":"https://secwatch.observer/filing/0001439222-25-000087","json":"https://secwatch.observer/filing/0001439222-25-000087.json","markdown":"https://secwatch.observer/filing/0001439222-25-000087.md","text":"https://secwatch.observer/filing/0001439222-25-000087.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1439222/000143922225000087/0001439222-25-000087-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1439222/000143922225000087/agio-20250731.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T22:16:38.020688+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}